37
APPROACH TO CONGENTAL HEMOLYTIC ANEMIAS Dr. Somendra Shukla Fellow Neonatology

Approach to Congental Hemolytic Anemias

Embed Size (px)

Citation preview

Page 1: Approach to Congental Hemolytic Anemias

APPROACH TO CONGENTAL HEMOLYTIC ANEMIAS

Dr. Somendra ShuklaFellow Neonatology

Page 2: Approach to Congental Hemolytic Anemias

Other questions to guide you

Is this acute or chronic? Is this acute or chronic? Is there a family history? Is there a family history? Does the child appear ill, or have signs of Does the child appear ill, or have signs of systemic disease? systemic disease? Are the liver and spleen large? Are the liver and spleen large? (extramedullary extramedullary sites of sites of hematopoiesis hematopoiesis) Exposure to infectious disease: HIV, Exposure to infectious disease: HIV, malaria, dengue malaria, dengue

Page 3: Approach to Congental Hemolytic Anemias

But first, is there really anemia?

• Anemia: Central venous hemoglobin < 13 g/dL or capillary hemoglobin < 14.5 g/dL in infant > 34 weeks and 0-28 days old

Page 4: Approach to Congental Hemolytic Anemias
Page 5: Approach to Congental Hemolytic Anemias

The Three Primary Measures

MeasurementA. RBC count (RCC) 5 million B. Hemoglobin 15 g%C. Hematocrit (PCV)45

A x 3 = B x 3 = C - This is the rule of thumbCheck whether this holds good in a given result

If not -indicates micro or macrocytosis or hypochro.

Page 6: Approach to Congental Hemolytic Anemias

The Three Derived Indiceseasurement Normal

A. RCC 5 million B. Hemoglobin 15 g%C. Hematocrit 45 %

MCV C ÷ A x 10 = 90 flMCH B ÷ A x 10 = 30 pgMCHC (%) B ÷ C x 100 = 33%

Page 7: Approach to Congental Hemolytic Anemias

Anemia – Second Test

RETICULOCYTE COUNT %

NormalLess than 2%

• ‘RBC to be’ or Apprentice RBC• Fragments of nuclear material• RNA strands which stain blue

Page 8: Approach to Congental Hemolytic Anemias

Reticulocyte

No definite nucleus

Reticulum of RNA

Deep blue staining

Light blue cytoplasm

Cell size about 10 µ

Page 9: Approach to Congental Hemolytic Anemias

Reticulocytes

Leishman’sSupravital

Page 10: Approach to Congental Hemolytic Anemias

Reticulocyte Production IndexFor example, the RPI is calculated as follows

Reticulocyte count 9%Hb content 7.5 g%1. Correction for Anemia

= 9 x (7.5 ÷ 15) = 9 x 0.5 = 4.5 %2. Correction for life span

4.5 ÷ 2 = 2.25 %3. Thus, the RPI is 2.25

Page 11: Approach to Congental Hemolytic Anemias

www.drsarma.in

Anemia

Hypoproliferative Hemolytic

RPI < 2 RPI > 2

Page 12: Approach to Congental Hemolytic Anemias

The Reticulocyte production index (RPI, also called a corrected reticulocyte count)

•raw reticulocyte count is misleading in anemic patients. •reticulocyte count is not really a count but rather a percentage: it reports the number of reticulocytes as a percentage of the number of red blood cells. •In anemia, the patient's red blood cells are depleted, creating an erroneously elevated reticulocyte count

Page 13: Approach to Congental Hemolytic Anemias

www.drsarma.in

Workup – Third Test

• The next step is ‘What is the size of RBC’ ?• MCV indicates the Red cell volume (size)• Both the MCH & MCHC tell Hb content of RBC• If the RPI is 2 or less• We are dealing with either

– Hypoproliferative Anemia (lack of raw material)– Maturation defect with less production– Bone marrow suppression (primary/ secondary)

Page 14: Approach to Congental Hemolytic Anemias

www.drsarma.in

Mean Cell Volume (MCV)

• RBC size is measured indirectly by• The Mean Cell Volume (MCV) and RDW

Microcytic

< 80 fl

MCV

Normocytic Macrocytic

80 -100 fl > 100 fl

< 6.5 µ 6.5 - 9 µ > 9 µ

Page 15: Approach to Congental Hemolytic Anemias

www.drsarma.in

Anemia Workup - MCV

Microcytic

MCV

Normocytic Macrocytic

Iron Deficiency (IDA)Chronic InfectionsThalassemiasHemoglobinopathiesSideroblastic Anemia

Chronic diseases, CKDEarly IDAHemoglobinopathiesPrimary marrow disordersCombined deficienciesIncreased destruction

Megaloblastic anemiasLiver disease/alcoholHemoglobinopathiesMetabolic disordersMarrow disordersIncreased destruction

Page 16: Approach to Congental Hemolytic Anemias

Presentation of hemolytic anemia

• Jaundice is usually the first symptom• Compensatory reticulocytosis• Pallor presents after 48 hours of age• Unconjugated hyperbilirubinemia of > 10-12

mg/dL• Tachypnea and hepatosplenomegaly may be

present

Page 17: Approach to Congental Hemolytic Anemias

Hemolytic Anemia

• Definition:– Those anemias which result from an increase in

RBC destruction

• Classification:– Congenital / Hereditary– Acquired

Page 18: Approach to Congental Hemolytic Anemias

Laboratory Evaluation of HemolysisExtravascular Intravascular  

HEMATOLOGIC

Routine blood filmReticulocyte countBone marrow examination

Polychromatophilia

Erythroid hyperplasia

Polychromatophilia

Erythroid hyperplasia

 

PLASMA OR SERUM

BilirubinHaptoglobinPlasma hemoglobinLactate dehydrogenase

Unconjugated , Absent N/ (Variable)

UnconjugatedAbsent (Variable)

 

URINEBilirubinHemosiderinHemoglobin

000

0++ severe cases  

Page 19: Approach to Congental Hemolytic Anemias

Inherited or acquired:

• Inherited HA are usually caused by intrinsic defect.• While acquired HA are caused by an extrinsic

defect.• However there are some exceptions: Paroxysmal

nocturnal haemoglobinuria (PNH) which is an acquired intrinsic defect, and severe hereditaryG6PD enz deficiency which requires the presence of an extrinsic trigger such as the antimalarial drug for the intrinsic defect to manifest.

Page 20: Approach to Congental Hemolytic Anemias

Hemoglobinuria

Page 21: Approach to Congental Hemolytic Anemias

Classification of Hemolytic Anemias

Hereditary 1. Abnormalities of RBC interior a.Enzyme defects: G-6-PD def,PK def b.Hemoglobinopathies 2. RBC membrane abnormalities a. Hereditary spherocytosis etc. b. PNH

 

Acquired c. Spur cell anemia3. Extrinsic factors a. Hypersplenism b. Antibody: immune hemolysis c. Mechanical trauma: MAHA d. Infections, toxins, etc

 Ref : Harrison’s

Page 22: Approach to Congental Hemolytic Anemias

Features of HEMOLYSISBilirubin

LDHReticulocytes, n-RBC

Haptoglobulins+ve Urinary hemosiderin, Urobilinogen

Blood Film

Spherocytes No spherocytes Fragmentation

DCT +ve DCT –ve

AI Hemolysis H. Sherocytosis Malaria, Clostidium Hereditery enzymopathies Microangiopathic,

Traumatic

Page 23: Approach to Congental Hemolytic Anemias

Red Cell Membrane Defects

1.Hereditary Spherocytosis– Usually inherited as AD disorder– Defect: Deficiency of Beta Spectrin or Ankyrin

Loss of membrane in Spleen & RES becomes more spherical Destruction in Spleen

Page 24: Approach to Congental Hemolytic Anemias

RBC Membrane

Page 25: Approach to Congental Hemolytic Anemias

– C/F:• Asymptomatic• Fluctuating hemolysis• Splenomegaly• Pigmented gall stones- 50%

Page 26: Approach to Congental Hemolytic Anemias

Complications

• Clinical course may be complicated with Crisis:– Hemolytic Crisis: associated with infection– Aplastic crisis: associated with Parvovirus infection

Page 27: Approach to Congental Hemolytic Anemias

• Inv:– Test will confirm Hemolysis– P Smear: Spherocytes– Osmotic Fragility: Increased

Screen Family members

Page 28: Approach to Congental Hemolytic Anemias

Osmotic Fragility

Page 29: Approach to Congental Hemolytic Anemias

• Management:– Folic Acid 5mg weekly, prophylaxis life long– Spleenectomy– Blood transfusion in Ac, severe hemolytic crisis

Page 30: Approach to Congental Hemolytic Anemias

2.Hereditary Elliptocytosis• Equatorial Africa, SE Asia• AD / AR• Functional abnormality in one or more anchor

proteins in RBC membrane- Alpha spectrin , Protein 4.1

• Usually asymptomatic• Mx: Similar to H. spherocytosis• Variant:

3.SE-Asian ovalocytosis:• Common in Malaysia , Indonesia…• Asymptomatic-usually• Cells oval , rigid ,resist invasion by malarial parasites

Page 31: Approach to Congental Hemolytic Anemias

Elliptocytosis

Page 32: Approach to Congental Hemolytic Anemias

Red Cell Enzymopathies

• Physiology:– EM pathway: ATP production– HMP shunt pathway: NADPH & Glutathione

production

Page 33: Approach to Congental Hemolytic Anemias

1. Glucose-6-Phosphate Dehydrogenase ( G6PD ) Deficiency– Pivotal enzyme in HMP Shunt & produces NADPH

to protect RBC against oxidative stress–Most common enzymopathy -10% world’s

population–Protection against Malaria–X-linked

Page 34: Approach to Congental Hemolytic Anemias

(Oxidised form)(Reduced form)

Page 35: Approach to Congental Hemolytic Anemias

• Clinical Features:– Acute drug induced hemolysis:

• Aspirin, primaquine, quinine, chloroquine, dapsone….– Chronic compensated hemolysis– Infection/acute illness– Neonatal jaundice– Favism

Page 36: Approach to Congental Hemolytic Anemias

• Inv:– e/o non-spherocytic intravascular hemolyis– P. Smear: Bite cells, blister cells, irregular

small cells, Heinz bodies, polychromasia– G-6-PD level

• Treatment: – Stop the precipitating drug or treat the

infection– Acute transfusions if required

Page 37: Approach to Congental Hemolytic Anemias

2. Pyruvate Kinase Deficiency– AR– Deficient ATP production, Chronic hemolytic

anemia– Inv;

• P. Smear: Prickle cells• Decreased enzyme activity

– Treatment: • Transfusion may be required